Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: Results of a phase I study

International Journal of Colorectal Disease

Volumn 20, Issue 5, 2005, Pages 403-414

  Zbar, A P ^a,h   Thomas, H ^b   Wilkinson, R W ^c   Wadhwa, M ^d   Syrigos, K N ^e   Ross, E L ^c   Dilger, P ^d   Allen Mersh, T G ^f   Kmiot, W A ^a   Epenetos, A A ^e   Snary, D ^c   Bodmer, W F ^g  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^e ST GEORGE S HOSPITAL   (United Kingdom)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Anti idiotypic antibodies; Immunotherapy; Monoclonal antibody therapy

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; IRINOTECAN; LYMPHOCYTE ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CANCER LOCALIZATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG RESPONSE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; IMMUNOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNE SERA; IMMUNITY, MUCOSAL; INJECTIONS, INTRADERMAL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; TREATMENT OUTCOME;

EID: 9644277675     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-004-0726-x     Document Type: Article

References (43)

1. Mellstedt H (2003) Monoclonal antibodies in human cancer. Drugs Today (Barc) 39 [Suppl]:C1-C16
2. Mellstedt H, Frodin J-E, Masucci G, Ragnhammar, Fagerberg J, Hjelm AL, Shetye J, Wersall P, Osterborg A (1991) The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 18:462-477 1:STN:280:By2D383mtlE%3D
3. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirsch R, Pichlmayr R et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177-1183 10.1016/ S0140-6736(94)92398-1
4. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R (1998) Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven year outcome of a multicenter randomized trial. J Clin Oncol 16:1788-1794 1:CAS:528:DyaK1cXjtFOqs7w%3D
5. Punt CJA, Nagy A, Douillard JY et al (2001) Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: Results of a phase III study. Proc Am Soc Clin Oncol 20:123(A)
6. Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones E, Dethling J, Colman J, Coward L, MacGregor S (2002) Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: A randomised study. Lancet 360:671-677 10.1016/ S0140-6736(02)09836-7
7. Herlyn D, Koprowski H (1981) Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int J Cancer 27:769-774 1:CAS:528:DyaL3MXksF2ku7g%3D
8. Adams DO, Hall T, Steplewski Z, Koprowski H (1984) Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype containing increasing numbers of macrophages activated for distinctive form of antibody dependent cytolysis. Proc Natl Acad Sci USA 81:3506-3510 1:CAS:528:DyaL2cXktlOjtrc%3D
9. Jerne NK (1974) Towards a network theory of the Immune system. Ann Immunol (Paris) 125C:373-389 1:STN:280:CSqC28zjtFM%3D
10. Fagerberg J, Frodin J-E, Wigzell H, Mellstedt H (1993) Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy? Cancer Immunol Immunother 37:264-270 10.1007/BF01518521
11. Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, Bhattacharya-Chatterjee M (1995) Immune response to the carcinoembryonic antigen in patients with an anti-idiotype antibody vaccine. J Clin Invest 96:334-352 1:CAS:528:DyaK2MXmslyqs7k%3D
12. Durrant LG, Denton GWL, Jacobs E, Mee M, Moss R, Austin EB, Baldwin RW, Hardcastle JD, Robins RA (1992) An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumors. Int J Cancer 50:811-816 1:CAS:528:DyaK38Xitlenur8%3D
13. Richman PI, Bodmer WF (1987) Monoclonal antibodies to human colorectal epithelium: Markers for differentiation and tumor characterization. Int J Cancer 39:317-328 1:STN:280:BiiC3snjtVc%3D
14. Lunniss PJ, Skinner S, Britton KE, Granowska M, Morris G, Northover JM (1999) Effect of radioimmunoscintigraphy on the management of recurrent colorectal cancer. Br J Surg 86:244-249 10.1046/j.1365-2168.1999.01008.x
15. Kim JC, Kim WS, Ryu JS, Oh SJ, Lee DH, Koo KH, Roh SA, Kim HC, Yu CS, Kang GH, Bodmer WF (2000) Applicability of CEA-specific monoclonal antibodies to radioimmunoguided surgery for human colorectal carcinoma. Cancer Res 60:4825-4829 1:CAS:528:DC%2BD3cXmsFWhs7k%3D
16. Granowska M, Jass JR, Britton KE, Northover JM (1989) A prospective study of the use of 111 In-labelled monoclonal antibody against CEA in colorectal cancer and of some biological factors affecting its uptake. Int J Colorect Dis 4:97-108 1:STN:280:BiaA3M%2FislI%3D
17. Durbin H, Young S, Stewart LM, Wrba F, Rowan AJ, Snary D, Bodmer WF (1994) An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3. Proc Natl Acad Sci USA 91:4313-4317 1:CAS:528:DyaK2cXktVKrt7g%3D
18. Stewart LM, Young S, Watson G, Mather SJ, Bates PA, Band HA, Wilkinson RW, Ross EL, Snary D (1999) Humanisation and characterization of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen. Cancer Immunol Immunother 47:299-306 10.1007/s002620050534
19. Begent RHJ, Searle F, Keep PA et al (1986) Operation manual for control, production, preclinical toxicity and phase I trials of anti-tumour antibodies and drug-antibody conjugates. Joint Committee Cancer Research Campaign. Br J Cancer 54:557-568 3756089
20. Bos JD, van Garderen ID, Krieg SR, Poulter LW (1986) Different in situ distribution patterns of dendritic cells having Langerhans (t6+) and interdigitating (RFD1+) cell immunophenotype in psoriasis, atopic dermatitis and other inflammatory dermatoses. J Invest Dermatol 87:358-361 10.1111/1523-1747.ep12524811
21. Betjes MG, Haks MC, Tuk CW, Beelen RH (1991) Monoclonal antibody EBM11 (anti-CD68) discriminates between dendritic cells and macrophages after short-term culture. Immunobiology 183:79-87 1:STN:280:By2D3sbnsFw%3D
22. LaFontaine GS, Hansen HJ, Weiss BF et al (1988) Enzyme immunoassay for the detection of circulating immunoglobulins in humans to mouse monoclonal antibody (HAMA). 3rd International Conference of Monoclonal Antibody Immunoconjugates for Cancer, San Diego, 4-6 February 1998. Abstract 77
23. Kosmas C, Epenetos AA, Courtenay-Luck NS (1991) Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. Br J Cancer 73:494-500
24. Neuhaus TJ, Wadhwa M, Callard R, Barratt TM (1995) Increased IL-2, IL-4 and interferon-gamma (IFN-γ) in steroid-sensitive nephrotic syndrome. Clin Exp Immunol 100:475-479 1:STN:280:ByqB1M3jvFM%3D
25. M Wadhwa C Bird P Dilger 2000 Quantitative biological assays for cytokines In: FR Balkwill (ed) Cytokine cell biology: A practical approach 3rd edn Oxford University Press Oxford 207-239
26. Bird C, Wadhwa M, Thorpe R (1991) Development of immunoassays for human IL-3 and IL-4, some of which discriminate between different recombinant DNA-derived molecules. Cytokine 3:562-567 10.1016/1043-4666(91)90482-S
27. Maxwell-Armstrong CA, Durrant LG, Buckley TJ, Scholefield JH, Robins RA, Fielding K, Monson JR, Guillou PJ, Calvert H, Carmichael J, Hardcastle JD (2001) Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer 84:1441-1446 10.1054/ bjoc.2001.1725
28. Gruber R, van Haarlem LJM, Warnaar SO, Holz E, Riethmuller G (2000) The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody 17-1A. Cancer Res 60:1921-1926 1:CAS:528:DC%2BD3cXisVynu70%3D
29. Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U, Raab R, Ross AH, Jaksche H, Scriba M et al (1987) Anti-idiotype immunization of cancer patients: Modulation of the immune response. Proc Natl Acad Sci USA 84:8055-8059 1:STN:280:BieD28fltlA%3D
30. Kirman I, Jenkins D, Fowler R, Whelan RL (2003) Naturally occurring antibodies to epithelial cell adhesion molecule (EpCAM). Dig Dis Sci 48:2306-2309 10.1023/B:DDAS.0000007867.25896.ce
31. Durrant LG, Buckley DJ, Spendlove I, Robins RA (1997) Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumour T-cell immunity. Hybridoma 16:23-26 1:STN:280:ByiB3sbks1Y%3D
32. Friguet B, Chaffotte A, Djavadi-Ohanianace L, Godberg ME (1985) Measurements of the true affinity constant in solution of antigen-antibody complexes by ELISA. J Immunol Methods 77:305 10.1016/ 0022-1759(85)90044-4
33. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL (1998) Immune cells in the tumor microenvironment: Mechanisms responsible for signaling and functional defects. J Immunother 21:295-308 1:CAS:528:DyaK1cXkvVSqu70%3D
34. Hjelm Skog AL, Wadhwa M, Hassan M, Gharizadeh B, Bird C, Ragnhammar P, Thorpe R, Mellstedt H (2001) Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody, 17-1A, granulocyte macrophage colony-stimulating factor and IL-2. Clin Cancer Res 7:1163-1170 1:STN:280:DC%2BD3M3lt1ensQ%3D%3D
35. Pervin S, Sherratt A, Wang H-T et al (1996) Proliferation of T cells from colon cancer patients with peptides based on the structure of an anti-idiotype antibody mimicking CEA. Am Assoc Cancer Res 37:473-474 (A3231)
36. Lanzavecchia A, Abrignani S, Scheidegger D, Obrist R, Dorken B, Moldenhauer G (1988) Antibodies as antigens: The use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med 167:345-352 10.1084/jem.167.2.345
37. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clones. I. Definition according to lymphokine activities and secreted proteins. J Immunol 136:2348-2357 1:CAS:528:DyaL28XhvVClsbk%3D
38. Pellegrini P, Berghella A-M, Del Beato T, Cicia S, Adorno D, Casciani CU (1996) Dysregualtion in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42:1-8 10.1007/ s002620050244
39. Tsitsilonis OE, Tsavaris NB, Kosmas C, Gouveris P, Papalambros E (2003) Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: A pilot study. J Chemother 15:387-393 1:CAS:528:DC%2BD3sXptlCktr8%3D
40. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC (1995) Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 87:1478-1483 1:CAS:528:DyaK2MXpsVSms74%3D
41. Takamaku K, Baba K, Arinaga S, Li J, Mori M, Akiyoshi T (1996) Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: Enhancement with interferon gamma. Cancer Immunol Immunother 43:220-225 10.1007/ s002620050325
42. Ragnhammar P, Fagerberg J, Frodin JE, Hjelm AL, Lindemalm C, Magnusson I, Masucci G, Mellstedt H (1993) Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced. Int J Cancer 53:751-758 1:STN:280:ByyC1MvjvVM%3D
43. Flieger D, Spengler U, Beier I, Kleinschmidt R, Hoff A, Varvenne M, Sauerbruch T, Schmidt-Wolf I (1999) Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines. Hybridoma 18:63-68 1:CAS:528:DyaK1MXit1ahsL0%3D